Asia-Pacific peptide therapeutics market is estimated to project a CAGR of 6.7%, during the forecast period. The growth of the market across the Asia-Pacific region is mainly attributed to the shifting age, rising disposable income, high R&D activities, among others. Additionally, the increasing activity of global players across the region through various mergers and acquisitions will also influence the growth of the peptide therapeutics market. China will be considered as a leading region for the peptide therapeutics market across the Asia-Pacific region. The leading position of china in the market is attributed to the strong healthcare of the country.
To Request a Sample of our Report on Asia-Pacific Peptide Therapeutics Market: https://www.omrglobal.com/request-sample/asia-pacific-peptide-therapeutics-market
Asia-Pacific peptide therapeutics market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into parenteral administration and oral administration. On the basis of application, the market is segmented into cancer, metabolic disorder (diabetes & obesity), gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others including chronic kidney diseases, osteoporosis, and autoimmune disorder. Among these applications, metabolic disorder dominates the market in Asia-Pacific.
Geographically, the Asia-Pacific peptide therapeutics market is segmented into China, Japan, India, and the Rest of Asia-Pacific. China contributed the major share in the Asia-Pacific peptide therapeutics market and is expected to retain its position during the forecast period. The increasing number of drug approvals are also expected to provide expansion opportunities for the peptide therapeutics market. India is expected to project the fastest growth rate in the Asia-Pacific market, owing to the high prevalence of cancer and large mortality due to cancer, along with the improving healthcare infrastructure of the country.
(Get 15% Discount on Buying this Report)
A full Report of Asia-Pacific Peptide Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-peptide-therapeutics-market
Asia-Pacific Peptide Therapeutics Market Segmentation
By Route of Administration
- Metabolic Disorder
- Gastrointestinal Disorders
- Central Nervous System Disorders
- Respiratory Disorders
- Others (Kidney Disorder and Autoimmune Disorder)
Rest of Asia-Pacific
- Amgen, Inc.
- Amgen Inc. in Asia-Pacific
- Amgen Inc. in Peptide Therapeutics Landscape
- Recent Developments
- Astellas Pharma Inc.
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- Novartis International AG
- Novo Nordisk A/S
- Simcere Pharmaceutical Group
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Qingdao Primedicine Pharmaceutical Co. Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-peptide-therapeutics-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit Orion Market Research
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404